US Patent 9901623 Rapid-acting insulin compositions
Patent 9901623 was granted and assigned to Eli Lilly and Company on February, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 19 Jan, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 7 Dec, 2023
Golden AI
Edits made to:
Article (+321 characters)
Article
Patent abstract
The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
Edits on 15 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09901623 Rapid-acting insulin compositions US Patent 9901623 Rapid-acting insulin compositions
Infobox
Patent Number
0990162300
Patent Number
990162300
Edits on 3 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
099016230
Date of Patent
February 27, 2018
0Patent Application Number
152414120
Date Filed
August 19, 2016
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
099016230
Date of Patent
February 27, 2018
0Patent Application Number
152414120
Date Filed
August 19, 2016
0Patent Primary Examiner
Edits on 19 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09901623 Rapid-acting insulin compositions
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09901623
Date of patent
February 27, 2018
Patent application number
15241412
Date Filed
August 19, 2016
Patent primary examiner
Find more entities like US Patent 9901623 Rapid-acting insulin compositions
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
